Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Knee Osteoarthritis
Interventions: Platelet Rich Plasma, Normal Saline; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 40 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions: Glutathione, N-Acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Guillain-Barré Syndrome, Miller Fisher Syndrome
Interventions: Not listed
Lead sponsor: Erasmus Medical Center; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 26
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more

Conditions: Hysteroscopy, Hysteroscopy Technique, Fertility Issues, Uterus Abnormal, Gynecology, Visualization, Infertility Female
Interventions: Visual Saline Infusion, Hydrosonography; Device
Lead sponsor: Center for Reproductive Health & Gynecology; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Surgical Site Infection, Cesarean Section; Complications, Wound, Infection (Following Delivery), Postpartum Complication
Interventions: Steri3X, Control; Device · Other
Lead sponsor: University of Tennessee; Other
Eligibility: 16 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy
Interventions: Guselkumab (lyophilized formulation), Guselkumab (liquid formulation with PFS-U), Guselkumab (liquid formulation with PFS FID), Guselkumab (liquid formulation); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey

Conditions: Electronic Cigarettes
Interventions: E-cigarette Lab Session 15 watts, 10 mg nicotine, E-cigarette Lab Session 15 watts, 30 mg nicotine, E-cigarette Lab Session 30 watts, 10 mg nicotine, E-cigarette Lab Session 30 watts, 30 mg nicotine, Own Brand Session - E-cigarette, Own Brand Session - E-cigarette/Cigarette; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Appendicitis
Interventions: Non-operative treatment, Appendectomy; Other · Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 5 Years to 16 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Alopecia Areata
Interventions: 308-nm excimer laser to alopecia patch, Liquid light guide tip on laser; Device
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 6 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Migraine Headache
Interventions: Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg, Diphenhydramine 1mg/kg, max 50mg, Normal saline fluid bolus 20mL/kg, max 1000mL; Other · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 8 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Pain Management, Spinal Fusion, Scoliosis
Interventions: Intrathecal morphine, Extended Release Epidural Morphine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: CSF Flow Through the Shunt of a Hydrocephalus Patient
Interventions: ShuntCheck; Device
Lead sponsor: NeuroDx Development; Industry
Eligibility: Up to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcoma
Interventions: Non-Metastatic and Resectable, Metastatic and Un-resectable, No evidence of disease, under surveillance, ALT or WDLS; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Severe Sepsis With Septic Shock
Interventions: Interleukin-7, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mucormycosis
Interventions: Mucormycosis; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain, Postoperative
Interventions: diclofenac potassium (XP21L), Placebo; Drug
Lead sponsor: Xanodyne Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 4
States / cities: Austin, Texas • Houston, Texas • San Marcos, Texas + 1 more

Conditions: Sepsis
Interventions: Ubiquinol, Placebo; Drug · Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy; Drug · Procedure
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more

Conditions: Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
Interventions: Cytophone; Device
Lead sponsor: Cytoastra; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Fluid Balance
Interventions: Placebo beverage, kiwi-strawberry flavor, Experimental glycerol beverage, kiwi-strawberry flavor; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: entinostat, imatinib mesylate, laboratory biomarker analysis, pharmacological study, western blotting, immunohistochemistry staining method, flow cytometry, polymerase chain reaction, high performance liquid chromatography, mass spectrometry; Drug · Other · Genetic
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obstructive Sleep Apnea, Pregnancy, Obesity, Sleep
Interventions: Not listed
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

International Guillain-Barré Syndrome Outcome Study

UTERINE EVALUATION FOR THE IDENTIFICATION OF PATHOLOGY. This Study Will Compare the Intrauterine Pathology Detection Rate Between Standard of Care Hydrosonography, and a New Visual Saline Infusion Device Providing Direct Visualization of the Uterus.

The Use of Steri3X for Prevention of Post-operative Wound Infections in Cesarean Sections

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Effects of E-Cigarette Power and Nicotine Content in Dual Users and Vapers

Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children

Childhood Alopecia Areata Study Using the 308-nm Excimer Laser

Auricular Acupuncture vs SOC in Migraine HA

Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion

Physician Preference Study of ShuntCheck - Madsen

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Ubiquinol (Reduced COQ10) for Patients With Sepsis

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

In Vivo Liquid Biopsy of Melanoma (Cytophone)

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Effects of a Glycerol-Electrolyte Beverage on Fluid Balance in Healthy Euhydrated Men and Women

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy